Şunu aradınız:: bcrp (İngilizce - Hırvatça)

bcrp
om,

bcrp substrates
supstrati bcrp

mechanism: bcrp
mehanizam: bcrp

(bcrp inhibition)
(inhibicija bcrp-a)

interactions with bcrp
interakcije s bcrp-om

(intestinal bcrp inhibition)
(inhibicija bcrp-a u crijevima)

bcrp, mrp2, oat3 and oct1 substrates
supstrati bcrp, mrp2, oat3 i oct1

medicinal products transported by bcrp
lijekovi koji se prenose putem bcrp prijenosnika

(inhibition of oatp1b and bcrp)
(inhibicija oatp1b i bcrp-a)

(cyp3a4/5 or bcrp inhibition)
(inhibicija cyp3a4/5 i bcrp)

inhibition of oatp 1b1 and bcrp by daclatasvir
daklatazvir inhibira oatp1b1 i bcrp.

dasabuvir is an inhibitor of bcrp in vivo.
dasabuvir je inhibitor bcrp-a in vivo.

(inhibition of drug transporters oatp and bcrp)
(inhibicija prijenosnika lijekova oatp i bcrp)

(oatp1b1/3, bcrp transporter inhibition)
(inhibicija oatp1b1/3, bcrp prijenosnika)

bcrp, oatp1b1, oatp1b3 and p-gp substrates
bcrp, oatp1b1, oatp1b3 i p-gp supstrati

metabolite m-5 is a weak bcrp-substrate.
metabolit m-5 je slabi bcrp supstrat.

bedaquiline was not a substrate of mrp2 and bcrp in vitro.
bedakilin nije bio supstrat mrp2 i bcrp in vitro.

lapatinib inhibits the transport proteins bcrp and oatp1b1 in vitro.
lapatinib inhibira prijenosne proteine bcrp i oatp1b1 in vitro.

caution is advised when cresemba is given concomitantly with substrates of bcrp.
preporučuje se oprez kod istodobne primjene lijeka cresemba sa supstratima za bcrp.

expected due to inhibition of oatp 1b1 and/or bcrp by daclatasvir:
budući da daklatazvir inhibira oatp 1b1 i/ili bcrp, očekuje se: